HHS Senior Advisor O’Brien Emerges As Azar’s Lead On Drug Pricing In 2019

O’Brien assumes role from his late colleague and friend Dan Best as HHS closes out administrative items in the blueprint.

RollOfDollarswithPills_1200x675

The Trump Administration appears to be ramping up towards some kind of action on drug pricing early in the New Year.

More from Pricing Debate

More from Market Access